Clinical Trial Update: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on an anti-BCMA/GPRC5D CAR-T cell therapy for relapsed/refractory multiple myeloma, focusing on safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• anti-BCMA/GPRC5D CAR-T cell therapy (null)

Snippet

Sponsor: Xuzhou Medical University | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN